CSF biomarkers in different phenotypes of Parkinson disease

Journal of Neural Transmission

Volumn 119, Issue 4, 2012, Pages 455-456

  Jellinger, Kurt A ^a  

^a NONE

Author keywords

Clinical phenotypes; CSF biomarkers; Parkinson disease; Total tau A 42

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; PARKINSON DISEASE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREMOR; TREMOR DOMINANT PARKINSON DISEASE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHENOTYPE; TAU PROTEINS; TREMOR;

EID: 84863478529     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0736-0     Document Type: Article

References (18)

1. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080-1086
2. Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E (2010) Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement 6:104-109
3. Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, Trojanowski JQ (2008) Biomarkers for early detection of Alzheimer pathology. Neurosignals 16:11-18
4. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E, Ezquerra M, Rios J, Tolosa E (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 24:2203-2210
5. de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, Lehericy S, Dubois B, Sarazin M (2011) CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging. doi:10.1016/j. neurobiolaging.2011.1002.1022 (in print)
6. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
7. Jellinger KA (2010) Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 25:500
8. Jellinger KA, Mizuno Y (2003) Parkinson disease. In: Dickson DW (ed) Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. ISN Neuropath Press, Basel, pp 159-187
9. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ (2011) Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 17:61-64
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
11. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J (2010) CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 25:2682-2685
12. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64:850-855
13. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O (2011) Cerebrospinal fluid Tau/alphasynuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord. doi:10.1002/mds.23670 (in print)
14. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50:743-755
15. Prikrylova Vranova H, Mares J, Nevrly M, Stejskal D, Zapletalova J, Hlustik P, Kanovsky P (2010) CSF markers of neurodegeneration in Parkinson's disease. J Neural Transm 117:1177-1181
16. Prikrylova Vranova H, Mares J, Hlustik P, Nevrly M, Stejskal D, Zapletalova J, Obereigneru R, Kanovsky P (2011) Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J Neural Transm. doi:10.1007/s00702-00011-00708-00704 (in print)
17. Riverol M, Lopez OL (2011) Biomarkers in Alzheimer's disease. Front Neurol 2:46. doi:10.3389/fneur.2011.00046
18. Rösler N, Wichart I, Jellinger KA (2001) Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm 108:231-246